Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

US tariffs, economic gloom continue to hit Clarkson

(Sharecast News) - Shipping broker Clarkson reported weaker interim earnings as US tariffs and an uncertain economic environment continued to hit freight rates. Pre-tax profit for the six months to June 30 fell to £37.5m from £50m a year earlier. Revenues declined to £298m from £310m. The company said it expected annual earnings to be second half weighted.

Clarkson said changes in US government trade policy and a shifting tariff environment, contributed to uncertainty and complexities for chartering activity and asset markets in the first half of 2025.

"Aside from the container segment which experienced a near record increase in tonne-miles caused by disruption from the closure of the Red Sea, freight rates in other markets were lower compared with the first half of 2024," the company said on Monday.

"New EU and US sanctions and the conflict in the Middle East provided some support for energy markets in the first half of the year, although these short-term tailwinds were tempered by lower oil prices and an easing of demand."

"An accelerated unwinding of OPEC+ supply cuts, and new oil production coming online in Latin America, should provide support for tanker markets into the second half of the year."

Shares the company slumped 20% in March as 2024 earnings were hit by US trade tariffs, political tensions and economic weakness.

Reporting by Frank Prenesti for Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.